-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Yangtze River Pharmaceutical Group Beijing Haiyan Pharmaceutical Co.
Eslicarbazepine acetate is an S-licarbazepine acetate prodrug, which blocks the conduction of action potentials to inhibit the repeated abnormal discharge of brain neurons and control epileptic seizures
The original research eslicarbazepine acetate was jointly developed by Bial-Portela, Eisai, and Sumitomo Dainippon.
In China, the original eslicarbazepine acetate has not been approved for marketing, but the drug has been included in the "Second Batch of Encouraging Generic Drugs List" published on the National Health Commission website in March 2021
At present, a number of domestic companies have deployed the eslicarbazepine generic drug market
Epilepsy is one of the three major diseases of the human central nervous system.
According to data from Minai.
In addition to eslicarbazepine, three antiepileptic drugs, vigabatrin, brivaracetam and perampanel, have also been included in the list of encouraged generic drugs
Gamma-aminobutyric acid (GABA) is an analogue of γ-aminobutyric acid (GABA).
Buvaracetam, also known as brivaracetam, is similar in structure to levetiracetam.
The original research perampanel (Fycompa) is a highly selective and non-competitive AMPA-type glutamate receptor antagonist developed by Eisai.
In addition, China also approved the first imitation of lacosamide in 2019
